Advertisement

Hematology/Oncology, BreakingMed

ASCO: Larotrectinib Produces Durable Responses

TRK fusion targets multiple cancers Patients diagnosed with a variety of advanced cancers — from thyroid to breast cancer — appear to have durable responses when treated with larotrectinib (Vitrakvi), an agent that...

Read More

ASCO: Survival Benefit Emerges in ARAMIS

Darolutamide better in non-metastatic castration-resistant prostate cancer Men diagnosed with non-metastatic castration-resistant prostate cancer live longer if they are treated with darolutamide (Nubeqa) than placebo, the final...

Read More

Advertisement

For latest news and updates
Email-id is invalid

Meeting Coverage